ZIOPHARM Oncology, Inc. ZIOP
Day range unavailable
52-week range unavailable
- Market cap
- 187.12M
- Revenue (ttm)
- 398.00K
- Shares out
- 216.15M
- Forward P/E
- -2.55
- Beta
- 1.69
- Analysts
- Hold
- Price target
- 3.92 (+352.8%)
- Earnings date
- Feb 24, 2022
2Y -0.7743 (-47.21%)
Key statistics
- Enterprise value
- 123.71M
- PEG ratio
- 0.00
- Price / sales
- 470.14
- Price / book
- 2.71
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -36.75M
- Total cash
- 91.72M
- Total debt
- 29.63M
- Return on equity
- -84.01%
- Short % of float
- 16.91%
- 50-day average
- 1.07
- 200-day average
- 1.89
Analyst view
Consensus: hold
- Target (low)
- 1.50
- Target (mean)
- 3.92
- Target (high)
- 7.50
- Strong buy1
- Buy1
- Hold4
- Sell0
- Strong sell0
Next earnings
Feb 24, 2022
Expected Feb 24, 2022. Consensus EPS estimate -0.08.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2022 | Dec 1, 2021 | -0.09 | — | — | — |
| Nov 8, 2021 | Sep 1, 2021 | -0.15 | — | — | — |
| May 6, 2021 | Mar 1, 2021 | -0.11 | — | — | — |
| Feb 25, 2021 | Dec 1, 2020 | -0.10 | — | — | — |
| Nov 5, 2020 | Sep 1, 2020 | -0.09 | — | — | — |
| Aug 6, 2020 | Jun 1, 2020 | -0.10 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 9, 2021 | Raymond James | main | — | Market Perform |
| Aug 10, 2021 | Raymond James | down | Outperform | Market Perform |
| May 7, 2021 | Raymond James | main | — | Outperform |
| Mar 12, 2021 | Jefferies | down | Buy | Hold |
| Mar 1, 2021 | HC Wainwright & Co. | down | Buy | Neutral |
| Jun 19, 2020 | Jefferies | init | — | Buy |
About ZIOPHARM Oncology, Inc.
ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- ziopharm.com
News
Why Ziopharm Oncology Shares Rose 10.5% on Wednesday 
Stocks That Hit 52-Week Lows On Friday 
ZIOPHARM Oncology (ZIOP) Sees Hammer Chart Pattern: Time to Buy? 
ZIOPHARM Oncology, Inc. (ZIOP) CEO Kevin Boyle on Q3 2021 Results - Earnings Call Transcript 
Earnings Scheduled For November 8, 2021 
Ziopharm Oncology to Report Third Quarter Financial Results on November 8, 2021 
Best Penny Stocks To Buy Right Now? 3 Short Squeeze Stocks To Watch - 36 Biggest Movers From Yesterday
ZIOP Stock: Why It Decreased Today 
Ziopharm Oncology Announces Strategic Reduction in Workforce and Extension in Cash Runway
Your note
Sign in to keep a note on ZIOP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAFFA RAFFAELE | Officer | Stock Award(Grant) | May 16, 2021 | 280,645 |
| BOWDEN CHRISTOPHER J | Director | Stock Award(Grant) | Mar 3, 2021 | 4,167 |
| BOYLE KEVIN S. SR | Chief Executive Officer | Stock Award(Grant) | Aug 29, 2021 | 875,000 |
| BUCHI J. KEVIN CPA | Director | Stock Award(Grant) | Mar 3, 2021 | 4,167 |
| HADFIELD ROBERT | Officer | Stock Award(Grant) | Mar 3, 2021 | 176,819 |
| HAGEN HEIDI | Director | Purchase | Sep 1, 2021 | 145,889 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.84% | 16,935,724 | 30.82M | Sep 29, 2021 |
| MSD Partners, L.P. | 7.01% | 15,151,516 | 27.58M | Sep 29, 2021 |
| Discovery Capital Management, LLC | 5.80% | 12,546,493 | 22.83M | Sep 29, 2021 |
| Vanguard Group, Inc. (The) | 5.73% | 12,385,833 | 22.54M | Sep 29, 2021 |
| State Street Corporation | 5.40% | 11,676,032 | 21.25M | Sep 29, 2021 |
| JP Morgan Chase & Company | 1.70% | 3,672,398 | 6.68M | Sep 29, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 3.36% | 7,254,095 | 10.08M | Nov 29, 2021 |
| Vanguard Total Stock Market Index Fund | 2.69% | 5,818,626 | 10.59M | Sep 29, 2021 |
| iShares Russell 2000 ETF | 2.26% | 4,888,689 | 7.33M | Oct 30, 2021 |
| Vanguard Extended Market Index Fund | 1.46% | 3,152,801 | 5.74M | Sep 29, 2021 |
| iShares Russell 2000 Growth ETF | 0.76% | 1,639,747 | 2.46M | Oct 30, 2021 |
| iShares NASDAQ Biotechnology ETF | 0.73% | 1,579,695 | 2.37M | Oct 30, 2021 |